Although the CPQ-PRKDC fusion is an attractive candidate for a therapeutic target in endometrial cancer, our knock-down experiments and Western blot analysis demonstrated that inhibiting CPQ-PRKDC- positive cell line proliferation was caused by suppression of the wild-type PRKDC expression and not suppression of the fusion transcript, which suggests that this fusion transcript might be a passenger alteration. This evidence concerns the gene PRKDC and endometrial cancer.